Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Linezolid

FDA-approved product (tablet, oral), marketed as Linezolid, Linezolid In Sodium Chloride 0.9% In Plastic Container, Zyvox.

Registered studies
50+
Lab records
63
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Linezolid
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Bacteriemia
  • Infection
  • Osteomyelitis
  • Pneumonia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antibacterials
FDA pharmacologic class
Oxazolidinone Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01XX08; FDA class Oxazolidinone Antibacterial

Repurposing investigation

Linezolid is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA89.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli1.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae27.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis82.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 39 of 44 lab records
  • E. coli: measured active in 1 of 4 lab records
  • K. pneumoniae: measured active in 2 of 8 lab records
  • M. tuberculosis: measured active in 5 of 7 lab records
Open Linezolid in ChEMBL Registered studies below
Show the 63 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Linezolid with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of Combinations of Novel Promising Drugs for Pulmonary Tuberculosis

    NCT07773610 · start 2026-07-23

    Registered record
    Registry ID
    NCT07773610
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    TBAJ-587 50 mg; Pretomanid 200mg; Linezolid 600Mg Tab; BTZ-043 250 mg or 500 mg; HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination); Quabodepistat (Q) 30 mg; Ganfeborole 20 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-07-23
    Completion
    2027-12-30
    Enrolment
    135

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    InterventionTBAJ-587 50 mg; Pretomanid 200mg; Linezolid 600Mg Tab; BTZ-043 250 mg or 500 mg +3 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Sorfequiline-based Regimens in Adults With Newly Diagnosed Drug-sensitive Pulmonary TB

    NCT07672405 · start 2026-07-09

    Registered record
    Registry ID
    NCT07672405
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    sorfequiline; Pretomanid; Linezolid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-07-09
    Completion
    2028-06-24
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    Interventionsorfequiline; Pretomanid; Linezolid
    PhasePhase 2
    Registry statusRecruiting

  • Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis

    NCT06590428 · start 2026-04-07

    Registered record
    Registry ID
    NCT06590428
    Conditions
    Rifampin-resistant Tuberculosis; Drug-resistant Tuberculosis
    Interventions
    Therapeutic Drug Monitoring for Linezolid
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-04-07
    Completion
    2029-12
    Enrolment
    280

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRifampin-resistant Tuberculosis; Drug-resistant Tuberculosis
    InterventionTherapeutic Drug Monitoring for Linezolid
    PhaseNot applicable
    Registry statusRecruiting

  • Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort

    NCT07268664 · start 2025-12-01

    Registered record
    Registry ID
    NCT07268664
    Conditions
    Rifampicin Resistant Tuberculosis; Pulmonary Tuberculosis; Tuberculosis; Drug-resistant Tuberculosis
    Interventions
    BLMZ
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2025-12-01
    Completion
    2028-08-31
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRifampicin Resistant Tuberculosis; Pulmonary Tuberculosis; Tuberculosis; Drug-resistant Tuberculosis
    InterventionBLMZ
    PhasePhase 3
    Registry statusNot yet recruiting

  • A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis

    NCT07209761 · start 2025-10-16

    Registered record
    Registry ID
    NCT07209761
    Conditions
    Pulmonary Tuberculosis
    Interventions
    BPaQM; BPaLM; BPaQ; BPaL
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-10-16
    Completion
    2028-09-29
    Enrolment
    532

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionBPaQM; BPaLM; BPaQ; BPaL
    PhasePhase 3
    Registry statusRecruiting

  • 6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province

    NCT07198685 · start 2025-09-30

    Registered record
    Registry ID
    NCT07198685
    Conditions
    Treat to Target; Treatment Duration
    Interventions
    bedaquiline; Delamanid (DLM); Linezolid (LZD); Levofloxacin; Cycloserine; Clofazimine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2025-09-30
    Completion
    2028-09-30
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTreat to Target; Treatment Duration
    Interventionbedaquiline; Delamanid (DLM); Linezolid (LZD); Levofloxacin +2 more
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Ultra-Short Regimen for Elderly DS-TB

    NCT07076225 · start 2025-07-25

    Registered record
    Registry ID
    NCT07076225
    Conditions
    Pulmonary Tuberculosis
    Interventions
    Bedaquiline (B); Sitafloxacin (S); Linezolid (L); Pyrazinamide (Z); Isoniazid (H); Rifampicin (R); Ethambutol (E)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2025-07-25
    Completion
    2030-07-31
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionBedaquiline (B); Sitafloxacin (S); Linezolid (L); Pyrazinamide (Z) +3 more
    PhasePhase 3
    Registry statusNot yet recruiting

  • Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis

    NCT05383742 · start 2023-12-07

    Registered record
    Registry ID
    NCT05383742
    Conditions
    Tuberculous Meningitis
    Interventions
    Rifampicin (RIF); Isoniazid (INH); Linezolid (LZD); Pyrazinamide (PZA); ethambutol (EMB); Rifampicin; Isoniazid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-12-07
    Completion
    2029-09-15
    Enrolment
    330

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculous Meningitis
    InterventionRifampicin (RIF); Isoniazid (INH); Linezolid (LZD); Pyrazinamide (PZA) +3 more
    PhasePhase 2
    Registry statusRecruiting

  • Linezolid for Syphilis Pilot Study

    NCT05548426 · start 2023-09-28

    Registered record
    Registry ID
    NCT05548426
    Conditions
    Syphilis
    Interventions
    Group B, Linezolid 10d; Group A, Penicillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-09-28
    Completion
    2026-08
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSyphilis
    InterventionGroup B, Linezolid 10d; Group A, Penicillin
    PhasePhase 2
    Registry statusActive not recruiting

  • Efficacy of Intravenous N-Acetylcysteine in Preventing Linezolid-Induced Thrombocytopenia in Critically Ill Patients

    NCT05944458 · start 2023-08-01

    Registered record
    Registry ID
    NCT05944458
    Conditions
    Linezolid; Antioxidant; Thrombocytopenia; Critical Illness; ICU
    Interventions
    N acetyl cysteine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-08-01
    Completion
    2025-06-01
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLinezolid; Antioxidant; Thrombocytopenia; Critical Illness +1 more
    InterventionN acetyl cysteine; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Repurposing Clinically Approved Drugs for Yaws With an Insight Into the Cutaneous Ulcer Disease Syndrome (Trep-AByaws)

    NCT05764876 · start 2023-03-14

    Registered record
    Registry ID
    NCT05764876
    Conditions
    Yaws; Cutaneous Ulcer
    Interventions
    Linezolid Oral Tablet; Azithromycin Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-03-14
    Completion
    2024-12-01
    Enrolment
    384

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionYaws; Cutaneous Ulcer
    InterventionLinezolid Oral Tablet; Azithromycin Oral Tablet
    PhasePhase 3
    Registry statusCompleted

  • BPaL(M) Regimen for the Treatment of MDR/RR-TB

    NCT05381194 · start 2022-12-13

    Registered record
    Registry ID
    NCT05381194
    Conditions
    Multidrug- and Rifampicin-resistant Tuberculosis
    Interventions
    BPaL(M) regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-12-13
    Completion
    2027-12
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultidrug- and Rifampicin-resistant Tuberculosis
    InterventionBPaL(M) regimen
    PhasePhase 4
    Registry statusRecruiting

  • Efficacy and Safety of Continuous Versus Intermittent Linezolid Infusion in Critically Ill Patients With Septic Shock

    NCT05813951 · start 2022-12-02

    Registered record
    Registry ID
    NCT05813951
    Conditions
    Treatment Efficacy
    Interventions
    Linezolid
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-12-02
    Completion
    2023-12-02
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTreatment Efficacy
    InterventionLinezolid
    PhaseNot applicable
    Registry statusUnknown

  • Pharmacokinetics and Pharmacodynamics of Linezolid Continuous and Intermittent Administration

    NCT05801484 · start 2022-07-01

    Registered record
    Registry ID
    NCT05801484
    Conditions
    Side-effect of Antibiotic; Efficacy; Pharmacokinetics; Critical Illness; Intensive Care Unit ICU
    Interventions
    Linezolid continuous infusion
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-07-01
    Completion
    2024-07-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSide-effect of Antibiotic; Efficacy; Pharmacokinetics; Critical Illness +1 more
    InterventionLinezolid continuous infusion
    PhaseNot applicable
    Registry statusUnknown

  • Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)

    NCT05369052 · start 2022-05-03

    Registered record
    Registry ID
    NCT05369052
    Conditions
    Diabetic Foot Infection
    Interventions
    contezolid acefosamil (IV)/contezolid (PO); Linezolid (IV and PO)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2022-05-03
    Completion
    2026-06-30
    Enrolment
    865

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Foot Infection
    Interventioncontezolid acefosamil (IV)/contezolid (PO); Linezolid (IV and PO)
    PhasePhase 3
    Registry statusRecruiting